Naltrexone effects on cortisol secretion in women and men in relation to a family history of alcoholism: Studies from the Oklahoma Family Health Patterns Project

Psychoneuroendocrinology

Volumn 37, Issue 12, 2012, Pages 1922-1928

  Lovallo, William R ^a,b   King, Andrea C ^c   Farag, Noha H ^d   Sorocco, Kristen H ^a,e   Cohoon, Andrew J ^a,b   Vincent, Andrea S ^f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Cortisol; Family history of alcoholism; Naltrexone; Opioid; Sex

Indexed keywords

HYDROCORTISONE; NALTREXONE; OPIATE RECEPTOR; PLACEBO;

ADULT; ALCOHOLISM; ARTICLE; CENTRAL OPIOID ACTIVITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FAMILY HISTORY; FEMALE; HORMONE RESPONSE; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NAUSEA; NERVOUS SYSTEM FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SALIVA LEVEL; VOMITING;

ADULT; AFFECT; ALCOHOLISM; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; FAMILY HEALTH; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PITUITARY-ADRENAL SYSTEM; RECEPTORS, OPIOID; SALIVA; SEX CHARACTERISTICS;

EID: 84869882616     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2012.04.006     Document Type: Article

References (53)

1. Adinoff B., Junghanns K., Kiefer F., Krishnan-Sarin S. Suppression of the HPA axis stress-response: implications for relapse. Alcohol. Clin. Exp. Res. 2005, 29:1351-1355.
2. al'Absi M., Hatsukami D., Davis G.L. Attenuated adrenocorticotropic responses to psychological stress are associated with early smoking relapse. Psychopharmacology (Berl.) 2005, 181:107-117.
3. al'Absi M., Wittmers L.E., Ellestad D., Nordehn G., Kim S.W., Kirschbaum C., Grant J.E. Sex differences in pain and hypothalamic-pituitary-adrenocortical responses to opioid blockade. Psychosom. Med. 2004, 66:198-206.
4. Ambrosi B., Bochicchio D., Ferrario R., Colombo P., Faglia G. Effects of the opiate agonist loperamide on pituitary-adrenal function in patients with suspected hypercortisolism. J. Endocrinol. Invest. 1989, 12:31-35.
5. American_Psychiatric_Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. 4th (text rev.) ed.
6. Andreasen N.C., Endicott J., Spitzer R.L., Winokur G. The family history method using diagnostic criteria. Reliability and validity. Arch. Gen. Psychiatry 1977, 34:1229-1235.
7. Bradberry J.C., Raebel M.A. Continuous infusion of naloxone in the treatment of narcotic overdose. Drug Intell. Clin. Pharm. 1981, 15:945-950.
8. Ceballos N.A., France C.R., al'Absi M. Influence of naltrexone administration on dehydroepiandrosterone sulfate levels in male and female participants. Biol. Psychol. 2007, 74:414-416.
9. Cohen M.R., Cohen R.M., Pickar D., Kreger D., McLellan C., Murphy D.L. Hormonal effects of high dose naloxone in humans. Neuropeptides 1985, 6:373-380.
10. Cohen M.R., Cohen R.M., Pickar D., Weingartner H., Murphy D.L. High-dose naloxone infusions in normals. Dose-dependent behavioral, hormonal, and physiological responses. Arch. Gen. Psychiatry 1983, 40:613-619.
11. Epperson C.N., Toll B., Wu R., Amin Z., Czarkowski K.A., Jatlow P., Mazure C.M., O'Malley S.S. Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug Alcohol Depend. 2010, 112:1-8.
12. Epstein A.M., King A.C. Naltrexone attenuates acute cigarette smoking behavior. Pharmacol. Biochem. Behav. 2004, 77:29-37.
13. Errico A.L., Parsons O.A., King A.C., Lovallo W.R. Attenuated cortisol response to biobehavioral stressors in sober alcoholics. J. Stud. Alcohol 1993, 54:393-398.
14. Farren C.K., O'Malley S., Grebski G., Maniar S., Porter M., Kreek M.J. Variable dose naltrexone-induced hypothalamic-pituitary-adrenal stimulation in abstinent alcoholics: a preliminary study. Alcohol. Clin. Exp. Res. 1999, 23:502-508.
15. Frew A.K., Drummond P.D. Negative affect, pain and sex: the role of endogenous opioids. Pain 2007, 132(Suppl. 1):S77-S85.
16. Garbutt J.C., Kranzler H.R., O'Malley S.S., Gastfriend D.R., Pettinati H.M., Silverman B.L., Loewy J.W., Ehrich E.W. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005, 293:1617-1625.
17. Greenfield S.F., Pettinati H.M., O'Malley S., Randall P.K., Randall C.L. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol. Clin. Exp. Res. 2010, 34:1803-1812.
18. Grossman A., Clement-Jones V. Opiate receptors: enkephalins and endorphins. Clin. Endocrinol. Metab. 1983, 12:31-56.
19. Grossman A., Rees L.H. The neuroendocrinology of opioid peptides. Br. Med. Bull. 1983, 39:83-88.
20. Hernandez-Avila C.A., Oncken C., Van Kirk J., Wand G., Kranzler H.R. Adrenocorticotropin and cortisol responses to a naloxone challenge and risk of alcoholism. Biol. Psychiatry 2002, 51:652-658.
21. Hoehe M. Influence of the menstrual cycle on neuroendocrine and behavioral responses to an opiate agonist in humans: preliminary results. Psychoneuroendocrinology 1988, 13:339-344.
22. Kiefer F., Jahn H., Otte C., Naber D., Wiedemann K. Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?. Biol. Psychiatry 2006, 60:74-76.
23. King, A.C., Cao, D., O'Malley, S.S., Kranzler, H.R., Cai, X., deWit, H., Matthews, A.K., Stakoviak, R.J. Effects of naltrexone on smoking cessation outcomes in nicotine dependent men and women. J. Clin. Psychopharmacol., in press.
24. King A.C., de Wit H., McNamara P.J., Cao D. Rewarding, stimulant, and sedative alcohol responses and relationship to future binge drinking. Arch. Gen. Psychiatry 2011, 68:389-399.
25. King A.C., de Wit H., Riley R.C., Cao D., Niaura R., Hatsukami D. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob. Res. 2006, 8:671-682.
26. King A.C., Schluger J., Gunduz M., Borg L., Perret G., Ho A., Kreek M.J. Hypothalamic-pituitary-adrenocortical (HPA) axis response and biotransformation of oral naltrexone: preliminary examination of relationship to family history of alcoholism. Neuropsychopharmacology 2002, 26:778-788.
27. Klein L.C., Jamner L.D., Alberts J., Orenstein M.D., Levine L., Leigh H. Sex differences in salivary cortisol levels following naltrexone administration. J. Appl. Biobehav. Res. 2000, 5:144-153.
28. Koob G.F., Le Moal M. Addiction and the brain antireward system. Annu. Rev. Psychol. 2008, 59:29-53.
29. Koob G.F., Rassnick S., Heinrichs S., Weiss F. Alcohol, the reward system and dependence. EXS 1994, 71:103-114.
30. Kreek M.J. Drug addictions: molecular and cellular endpoints. Ann. N.Y. Acad. Sci. 2001, 937:1749-6632.
31. Lee M.C., Wagner H.N., Tanada S., Frost J.J., Bice A.N., Dannals R.F. Duration of occupancy of opiate receptors by naltrexone. J. Nucl. Med. 1988, 29:1207-1211.
32. Leslie R.D., Prescott R.W., Kendall-Taylor P., Cook D., Weightman D., Ratcliffe J., Ingram M.C. Opiate receptor blockade and diurnal pituitary and adrenal hormone levels. Horm. Metab. Res. 1985, 17:86-89.
33. Ling W., Wesson D.R. Drugs of abuse-opiates. West J. Med. 1990, 152:565-572.
34. Lovallo W.R. Cortisol secretion patterns in addiction and addiction risk. Int. J. Psychophysiol. 2006, 59:195-202.
35. Lundberg U., Frankenhaeuser M. Pituitary-adrenal and sympathetic-adrenal correlates of distress and effort. J. Psychosom. Res. 1980, 24:125-130.
36. Meyer M.C., Straughn A.B., Lo M.W., Schary W.L., Whitney C.C. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J. Clin. Psychiatry 1984, 45:15-19.
37. Moncrieff J., Drummond D.C. New drug treatments for alcohol problems: a critical appraisal. Addiction 1997, 92:939-947. discussion 49-64.
38. O'Malley S.S., Cooney J.L., Krishnan-Sarin S., Dubin J.A., McKee S.A., Cooney N.L., Blakeslee A., Meandzija B., Romano-Dahlgard D., Wu R., Makuch R., Jatlow P. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch. Intern. Med. 2006, 166:667-674.
39. O'Malley S.S., Krishnan-Sarin S., Farren C., Sinha R., Kreek M.J. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl.) 2002, 160:19-29.
40. Ooteman W., Koeter M.W., Verheul R., Schippers G.M., van den Brink W. The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics. Eur. Neuropsychopharmacol. 2007, 17:558-566.
41. Ray L.A., Mackillop J., Leggio L., Morgan M., Hutchison K.E. Effects of naltrexone on cortisol levels in heavy drinkers. Pharmacol. Biochem. Behav. 2009, 91:489-494.
42. Roche D.J., Childs E., Epstein A.M., King A.C. Acute HPA axis response to naltrexone differs in female vs. male smokers. Psychoneuroendocrinology 2010, 35:596-606.
43. Salimetrics High Sensitivity Salivary Cortisol Enzyme Immunoassay Kit 2011.
44. Schuckit M.A., Gold E., Risch C. Plasma cortisol levels following ethanol in sons of alcoholics and controls. Arch. Gen. Psychiatry 1987, 44:942-945.
45. Sinha R., Fox H.C., Hong K.I., Hansen J., Tuit K., Kreek M.J. Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes. Arch. Gen. Psychiatry 2011, 68:942-952.
46. Sorocco K.H., Lovallo W.R., Vincent A.S., Collins F.L. Blunted hypothalamic-pituitary-adrenocortical axis responsivity to stress in persons with a family history of alcoholism. Int. J. Psychophysiol. 2006, 59:210-217.
47. Uhart M., Chong R.Y., Oswald L., Lin P.I., Wand G.S. Gender differences in hypothalamic-pituitary-adrenal (HPA) axis reactivity. Psychoneuroendocrinology 2006, 31:642-652.
48. Verebey K., Volavka J., Mule S.J., Resnick R.B. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin. Pharmacol. Ther. 1976, 20:315-328.
49. Vuong C., Van Uum S.H., O'Dell L.E., Lutfy K., Friedman T.C. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr. Rev. 2010, 31:98-132.
50. Wand G., McCaul M.E., Gotjen D., Reynolds J., Lee S. Confirmation that offspring from families with alcohol-dependent individuals have greater hypothalamic-pituitary-adrenal axis activation induced by naloxone compared with offspring without a family history of alcohol dependence. Alcohol. Clin. Exp. Res. 2001, 25:1134-1139.
51. Wand G.S., Mangold D., Ali M., Giggey P. Adrenocortical responses and family history of alcoholism. Alcohol. Clin. Exp. Res. 1999, 23:1185-1190.
52. Wand G.S., Mangold D., El Deiry S., McCaul M.E., Hoover D. Family history of alcoholism and hypothalamic opioidergic activity. Arch. Gen. Psychiatry 1998, 55:1114-1119.
53. Zimmerman M., Coryell W., Pfohl B., Stangl D. The reliability of the family history method for psychiatric diagnoses. Arch. Gen. Psychiatry 1988, 45:320-322.